Ajooni Biotech Limited

NSEI:AJOONI Stock Report

Market Cap: ₹862.9m

Ajooni Biotech Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Gursimran Singh

Chief executive officer

₹1.2m

Total compensation

CEO salary percentage100.0%
CEO tenure3.8yrs
CEO ownershipn/a
Management average tenure4.3yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Market Cool On Ajooni Biotech Limited's (NSE:AJOONI) Earnings Pushing Shares 25% Lower

Mar 20
Market Cool On Ajooni Biotech Limited's (NSE:AJOONI) Earnings Pushing Shares 25% Lower

We Ran A Stock Scan For Earnings Growth And Ajooni Biotech (NSE:AJOONI) Passed With Ease

Nov 10
We Ran A Stock Scan For Earnings Growth And Ajooni Biotech (NSE:AJOONI) Passed With Ease

We Ran A Stock Scan For Earnings Growth And Ajooni Biotech (NSE:AJOONI) Passed With Ease

Jul 13
We Ran A Stock Scan For Earnings Growth And Ajooni Biotech (NSE:AJOONI) Passed With Ease

If You Like EPS Growth Then Check Out Ajooni Biotech (NSE:AJOONI) Before It's Too Late

Feb 16
If You Like EPS Growth Then Check Out Ajooni Biotech (NSE:AJOONI) Before It's Too Late

Should Weakness in Ajooni Biotech Limited's (NSE:AJOONI) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 14
Should Weakness in Ajooni Biotech Limited's (NSE:AJOONI) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Did Ajooni Biotech Limited (NSE:AJOONI) Insiders Buy Up More Shares?

Dec 24
Did Ajooni Biotech Limited (NSE:AJOONI) Insiders Buy Up More Shares?

CEO Compensation Analysis

How has Gursimran Singh's remuneration changed compared to Ajooni Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

₹22m

Dec 31 2023n/an/a

₹18m

Sep 30 2023n/an/a

₹15m

Jun 30 2023n/an/a

₹12m

Mar 31 2023₹1m₹1m

₹11m

Dec 31 2022n/an/a

₹5m

Sep 30 2022n/an/a

₹9m

Jun 30 2022n/an/a

₹11m

Mar 31 2022₹2m₹2m

₹10m

Dec 31 2021n/an/a

₹11m

Sep 30 2021n/an/a

₹7m

Jun 30 2021n/an/a

₹4m

Mar 31 2021₹540k₹540k

₹4m

Compensation vs Market: Gursimran's total compensation ($USD14.37K) is below average for companies of similar size in the Indian market ($USD38.43K).

Compensation vs Earnings: Gursimran's compensation has been consistent with company performance over the past year.


CEO

Gursimran Singh (36 yo)

3.8yrs

Tenure

₹1,200,000

Compensation

Mr. Gursimran Singh had been the Chief Financial Officer of Prism Medico and Pharmacy Limited December 4, 2017 until May 16, 2023 and served as its Executive Director from April 01, 2017 to October 5, 2019...


Leadership Team

NamePositionTenureCompensationOwnership
Jasjot Singh
Chairman6.8yrs₹3.00m13.96%
₹ 120.5m
Gursimran Singh
CEO & Whole Time Directorno data₹1.20mno data
Partek Singh
Executive & Non-Independent Director7yrs₹600.00kno data
Swati Vijan
Company Secretary & Compliance Officer4.3yrs₹571.00kno data

4.3yrs

Average Tenure

36yo

Average Age

Experienced Management: AJOONI's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jasjot Singh
Chairman6.8yrs₹3.00m13.96%
₹ 120.5m
Gursimran Singh
CEO & Whole Time Director3.8yrs₹1.20mno data
Partek Singh
Executive & Non-Independent Director7yrs₹600.00kno data
Simmi Chhabra
Independent Non-Executive Woman Director6.8yrs₹30.00k0.037%
₹ 317.5k
Imteshwar Bhatia
Independent Non-Executive Director6.8yrs₹30.00kno data
Ramandeep Singh
Independent Non-Executive Director6.8yrs₹30.00kno data

6.8yrs

Average Tenure

36.5yo

Average Age

Experienced Board: AJOONI's board of directors are considered experienced (6.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.